Serratiopeptidase + Diclofenac PotassiumThird Party Manufacturing in India

Serratiopeptidase + Diclofenac Potassium works through a synergistic dual mechanism that combines potent cyclooxygenase inhibition with proteolytic enzyme activity for rapid and sustained resolution of pain and inflammation.

Diclofenac Potassium is a non-steroidal anti-inflammatory drug that inhibits both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the rate-limiting enzymes in the conversion of arachidonic acid to prostaglandin H₂, the precursor of prostaglandins, prostacyclin, and thromboxanes. By blocking prostaglandin synthesis at the peripheral tissue level, diclofenac reduces vasodilation, vascular permeability, oedema formation, and the sensitisation of nociceptive pain receptors. The potassium salt formulation offers faster absorption and a more rapid onset of analgesia compared to diclofenac sodium, making it preferred for acute pain conditions.

Serratiopeptidase is a zinc-containing metalloprotease enzyme isolated from Serratia marcescens that complements the NSAID action through a completely independent pathway. It breaks down fibrin and proteinaceous exudates at the inflammation site, thins inflammatory fluid collections, improves lymphatic drainage, and dissolves devitalised tissue surrounding the injured area. Unlike conventional anti-inflammatory agents, serratiopeptidase also inhibits bradykinin release, downregulates pro-inflammatory cytokines, and modulates cell-surface adhesion molecules that guide inflammatory cells to the target site. This dual pathway achieves faster oedema resolution and pain relief than either agent used alone.

Therapeutic Uses

Serratiopeptidase + Diclofenac Potassium is prescribed for the relief of:

• Acute Musculoskeletal Pain and Inflammation: Highly effective for sprains, strains, fractures, and soft tissue injuries where both pain relief and oedema reduction are required for functional recovery.
• Post-Operative Inflammation and Oedema: Used to accelerate recovery after dental extractions, orthopaedic surgery, and ENT procedures by reducing swelling and promoting faster wound healing.
• Rheumatoid and Osteoarthritis Flare-Ups: Provides symptomatic relief from joint swelling, stiffness, and pain during acute exacerbations of chronic arthritic conditions.
• Sinusitis and Respiratory Inflammation: The mucolytic and anti-oedema properties of serratiopeptidase help drain blocked sinuses and reduce mucosal swelling in acute and chronic sinusitis.
• Dental Inflammations: Prescribed for pericoronitis, periodontitis, post-extraction pain, and alveolar osteitis where infection and inflammation coexist.
• Traumatic Injuries: Used in sports medicine and accident care for rapid resolution of swelling and pain following contusions, haematomas, and ligament injuries.

Why Manufacturers Choose Serratiopeptidase + Diclofenac Potassium

This fixed-dose combination enjoys massive prescription volume across orthopaedic, dental, ENT, and general surgery practices in India. The dual-action formulation commands a premium price point compared to standalone NSAIDs, offering significantly better margins for PCD franchise partners and contract manufacturers. Indian pharmaceutical companies produce this combination in high volumes for both domestic consumption and export to Africa, Southeast Asia, and the Middle East. The manufacturing process requires standard tablet compression technology with enteric coating for the serratiopeptidase component to protect enzyme activity through the acidic gastric environment. Quality-conscious buyers specifically seek WHO-GMP certified manufacturers to ensure enzyme stability and consistent dissolution profiles across all production batches.

This makes Serratiopeptidase + Diclofenac Potassium one of the most sought-after combination products for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented pharmaceutical companies.